Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CAPN1 | P07384 | 6/20 | 0.32 |
| ▸ | RARA | P10276 | 1/20 | 0.30 |
| ▸ | RARB | P10826 | 1/20 | 0.30 |
| ▸ | RARG | P13631 | 1/20 | 0.30 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | PLAUR | Q03405 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6147589 | 0.89 | TAS1R3 (0.34) | SMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL6143646 | 0.83 | P4HTM (0.39) | SMN1; SMN2ALDH1A1HTTAKR1B1KDM4E | |
| SCHEMBL6148053 | 0.82 | RARA (0.44) | SMN1; SMN2ALDH1A1HTTRARARARB | |
| SCHEMBL6146166 | 0.82 | RARA (0.44) | SMN1; SMN2ALDH1A1HTTRARARARB | |
| SCHEMBL6147976 | 0.80 | UGCG (0.31) | — | |
| SCHEMBL6145636 | 0.77 | TAS1R3 (0.36) | SMN1; SMN2ALDH1A1AKR1B1KDM4ENPC1 | |
| SCHEMBL6148235 | 0.75 | RARA (0.43) | SMN1; SMN2ALDH1A1RARARARBRARG | |
| SCHEMBL6147365 | 0.75 | RARA (0.43) | SMN1; SMN2ALDH1A1RARARARBRARG | |
| SCHEMBL6148846 | 0.74 | RXRA (0.46) | RARARARBRARG | |
| SCHEMBL6017429 | 0.74 | CHRM2 (0.35) | RARARARBRARGAKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1280757-B1 | NEW GAMMA SELECTIVE RETINOIDS | HOFFMANN LA ROCHE (CH) | 2005-08-17 | — | — | EP | disclosed |
| US-6603012-B2 | RAR selective retinoid agonists | HOFFMANN-LA ROCHE INC. | 2003-08-05 | — | — | US | disclosed |
| EP-1280757-A2 | NEW GAMMA SELECTIVE RETINOIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-02-05 | — | — | EP | disclosed |
| US-20020026060-A1 | RAR selective retinoid agonists | F.HOFFMANN-LA ROCHE AG (CH) | 2002-02-28 | — | — | US | disclosed |
| WO-2001083438-A2 | NEW GAMMA SELECTIVE RETINOIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020026060-A1 | RAR selective retinoid agonists | RARA, RARG, RARB | SMN1; SMN2 3223/4885ALDH1A1 583/4885HTT 4018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.